Post clips from around the web..
FLASKWORKS' owned by NWBO, its individualized treatment production device, MIcroDen, has already been manufactured by CORNING and is currently being marketed to pharmas producing similar treatments requiring sterilized environments for culture/medication production. FLASKWORKS and Corning would not have had MicroDen bought from them by NWBO with stock options without having done their own analysis of the NWBO's profitability.
NWBO is ready to hit the ground running.
If the results were bad news, we would have heard by now. My bet is the final data is a go and NWBO is in the process of writing the article detailing scientifically its success and arranging for publication of positive results in a major medical journal. That takes time to fit into publication schedules. A treatment break thru of this magnitude is not simply publicized in a pedestrian press release. Maybe no. Maybe yes. I say yes!
Good news is coming!
----------
Here is an extract from
Herald-Tribune today's article:
"However, and this is a huge however, if the trial had failed, SEC rules require that they had to reveal that to investors within four days.
Instead, weeks have passed without a word, so by inference we now know the trial was a success. This is the largest and longest such trial ever run and the only one of more than 400 to reach a happy result.
The lead investigators and their collaborators are hard at work on a paper to be published in a major medical journal. Until then, the company is in a “quiet period.”"
-------------
I wish that we could really infer that the trial is a success. Fact is, the FDA makes that decision. They can't decide until they have an application and all of the supporting data. The odds of approval are higher now for sure, but currently there is no telling whether the FDA will move to make a label so NWBO can market/help people; or demand a PIV; or what... all I'm sayin' is that there will be a time to make yourself fat or get yourself slaughtered.
---------
Its getting clearer with each passing day that the TLD will be favorable! Action today may be leakage of data about to be released!!
--------
At this time very little downside risk. If this failed we would have known by now based on SEC 4 day rule. Remember, the FDA mandated cross over option in this trial so there is absolutely no way the would fail this study based on that fact. Agree, it may be more difficult to analyze but I am certain the statistics will be correctly identified. My money is on approval by the UK, Germany and Canada. LP knew that the FDA is a puppet for lobbyists so she was brilliant in her decision to develop the trial in 4 countries! Merry Christmas longs
